CYPRESS, Calif., Nov. 6, 2018 /PRNewswire-iReach/
WCCT Global, Inc., a multisite, full-service contract research organization (CRO) specializing in research services to the pharmaceutical, biotechnology and medical device industries, announces that Melton Affrime is appointed President and David Charlot appointed CEO.
Mel Affrime, PharmD, recently appointed Chief Scientific Officer and Board Director, will also serve WCCT Global as President. Dr. Affrime brings 30+ years of industry experience and has held executive-level clinical pharmacology positions at ICON PLC, Novartis Pharmaceuticals and Schering-Plough Research Institute. His expertise in early clinical development is well known throughout the pharmaceutical industry.
David Charlot, Chief Transformation Officer for WCCT Global since August 2018, was appointed CEO. Mr. Charlot brings 20+ years of diverse business, organizational development and turnaround experience. As Science 37's first CFO, he is well-versed in clinical research challenges and solutions.
Together, Dr. Affrime and Mr. Charlot will lead WCCT Global forward while ensuring continuity of services. Jon Rojas, was removed as President and CEO and is no longer employed by WCCT Global.
Dr. Affrime said "I have been with WCCT Global for 7 years, serving as the scientific lead for multiple projects and scientific initiatives including the development of our ethnobridging, special population, viral challenge, tobacco, and cannabinoid capabilities. I am thrilled with the opportunity to work together with David and our entire WCCT Global family to continue to strive to be the best early development CRO in our industry".
Mr. Charlot adds, "Mel is a tremendous asset to WCCT Global, and I'm confident that his leadership will bring breadth and depth to our clinical programs. My time spent working side-by-side with key players across the organization has revealed an untapped pool of terrific talent ready to transform WCCT into what it should be: a nimble, innovative, quick-to-respond CRO delivering unquestioned project quality. We will be responsive to our clients' needs and to our volunteer participants' contentment. Much remains to be done, but we are on our way."
Speaking on behalf of the Board, Gregory Hanson said, "We are convinced that WCCT Global's best days are ahead. The board is pleased with the progress being made by the new executive team. We now believe WCCT Global has the momentum to carry forward in being one of the premiere CROs."
About WCCT Global, Inc.
WCCT Global, Inc. is a full-service CRO offering clinical development services to the pharmaceutical, biotechnology, and medical device industries. As a drug development partner, WCCT collaborates with domestic and foreign innovator companies who need regulatory, program management, and strategic consulting support.
Media Contact: Mika Matsumura, WCCT Global, Inc., (714) 252-0700 x 1030, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global, Inc.